ClinicalTrials.gg
RecruitingNCT04354064Updated Feb 20, 2026

Circulating Tumor DNA (ctDNA) for Early Treatment Response Assessment of Solid Tumors

An observational study in Healthy Volunteer, Prostate Cancer and Head and Neck Cancer, sponsored by Washington University School of Medicine. Recruiting at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-02-20.

Sponsored by Washington University School of Medicine · Observational

How we know

From the registry’s dates

  • Started May 2019; still recruiting 7 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Other
Enrollment
100
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 23 studies in Prostatic Neoplasms by Washington University School of Medicine — 9 open to participants now, 11 under way, none of them phase 3. Prostatic Neoplasms · Washington University School of Medicine.

Started
2019
the only one that year
Observational
2 of 23
1 open now
Primary completion
2026-12
later than 1 of 10 live
Registered
11th of 23
by date

Among the 23 studies in Prostatic Neoplasms by Washington University School of Medicine, this one is the only one that started in 2019, is one of 2 observational ones, reaches primary completion later than 1 of the 10 other live ones, and was the 11th registered.

Prostatic Neoplasms

7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

9 of the 23 studies in Prostatic Neoplasms by Washington University School of Medicine are open now, in 1 country. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 9 open studies →

Where they have run

Who these studies take

Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies in Prostatic Neoplasms by Washington University School of Medicine, or all of them as a file.
02

Study summary

Earlier detection of disease recurrence will enable greater treatment options and has strong potential to improve patient outcomes. This project is translational and has the potential to lead to future translational research opportunities, including interventional trials in which therapeutic escalation is offered at the early circulating tumor DNA (ctDNA) molecular residual disease (MRD) detection timepoint. Ultimately, the integration of ctDNA into the clinical workflow has the potential to enhance cancer diagnosis, treatment, surveillance, and prognosis, and guide clinical decision-making in this era of personalized precision medicine.

03

Conditions studied

  • Healthy Volunteer
  • Prostate Cancer
  • Head and Neck Cancer
  • Esophageal Cancer
  • Genitourinary Cancer
  • Sarcoma
  • Breast Cancer
  • Colon Cancer
  • Gastrointestinal Cancer
  • Solid Tumor Cancer
  • Lung Cancer
  • Skin Cancer
  • Melanoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

  • This study will access data and specimens from patients who consented to specimen banks (approximately 3262 patients) There is a waiver of consent for this study regarding patient data banked under the tissue banks.
  • Healthy donors will be consented prior to sample acquisition (approximately 100 patients)

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Eligible healthy donors will be at least 18 years of age.

Exclusion criteria

Exclusion Criteria:

  • Healthy donors younger than 18 years of age
05

Study design

Observational model
Cohort
Time perspective
Other
Enrollment
100 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Healthy Donor Samples

    * Donation of blood and/or urine samples as often as bi-monthly and as many as 24 times in total * These samples will be used to generate reference data to compare patient data to and/or to correct stereotypic noise.

  • Samples from Repository and Banking Studies

    * Healthy prostate and/or blood and/or urine samples from Genitourinary Repository * Tissue, blood, and/or drain fluid samples from Head and Neck Banking studies * Tissue and/or blood samples from Esophageal Repository * Tissue and/or blood samples from Genitourinary Repository * Tissue and/or plasma from Sarcoma Tissue Bank * Tissue and/or plasma from Breast Cancer Bank * Tissue, plasma, and/or urine from GI Tissue and Blood Bank * Tissue, blood, and/or urine from Solid Tumor Bank * Tissue, blood, and/or urine from Lung Cancer Bank * Tissue and/or blood from Skin Cancer Bank * Tissue and/or blood from Pediatric Neurosurgery Tissue Bank

06

What researchers measure

Primary outcomes

  1. Freedom from progression

    -Defined as RECIST 1.1 based radiographic or clinical progression, with non-progressors censored at last radiographic follow-up

    Time frame: Through completion of study (estimated to be 6.5 years)

Secondary outcomes

  1. Event-free survival

    -Defined as post-treatment ctDNA detection or RECIST 1.1 based radiographic progression

    Time frame: Through completion of study (estimated to be 6.5 years)

  2. Disease-specific survival

    -Defined as death from cancer

    Time frame: Through completion of study (estimated to be 6.5 years)

  3. Overall survival

    -Defined as death from any cause

    Time frame: Through completion of study (estimated to be 6.5 years)

  4. Pathologic complete response rate

    Time frame: Through completion of study (estimated to be 6.5 years)

  5. Locoregional failure

    -Defined as clinical or radiographic progression within the localized tumor/treatment area or regional lymph nodes

    Time frame: Through completion of study (estimated to be 6.5 years)

  6. Distant-metastasis-free survival

    -Defined as clinical or radiographic progression outside the localized tumor/treatment area and regional lymph nodes

    Time frame: Through completion of study (estimated to be 6.5 years)

07

Study locations

1 of 1 sites recruiting
  • Washington University School of Medicine
    St Louis, Missouri 63110, United States
    Recruiting
    • Melissa Reimers, M.D. · Contactcbumb@wustl.edu · 314-362-7249
    • Melissa Reimers, M.D. · Principal investigator
    • Peter Harris, Ph.D. · Sub investigator
    • Re-I Chin, M.D. · Sub investigator
    • Hiram Gay, M.D. · Sub investigator
    • Wade Thorstad, M.D. · Sub investigator
    • Jose Zevallos, M.D., MPH · Sub investigator
    • Sidharth Puram, M.D., Ph.D. · Sub investigator
    • Varun Puri, M.D. · Sub investigator
    • Christopher Maher, Ph.D. · Sub investigator
    • Ha Dang, Ph.D. · Sub investigator
    • Paul Jones, B.A. · Sub investigator
    • Benjamin Tan, M.D. · Sub investigator
    • Zachary Smith, M.D. · Sub investigator
    • Eric Kim, M.D. · Sub investigator
    • Vivek Arora, M.D. · Sub investigator
    • Brian Van Tine, M.D., Ph.D. · Sub investigator
    • Angela Hirbe, M.D., Ph.D. · Sub investigator
    • Cynthia Ma, M.D., Ph.D. · Sub investigator
    • Imran Zoberi, M.D. · Sub investigator
    • Ryan Fields, M.D. · Sub investigator
    • Koushik Das, M.D. · Sub investigator
    • Ricardo Ramirez, M.D. · Sub investigator
    • David Chen, M.D., Ph.D. · Sub investigator
    • Nicholas Semenkovich, M.D., Ph.D. · Sub investigator
08

References and documents

Individual participant data

Plan to share: Yes — All of the individual participant data collected during the trial, after deidentification will be available for sharing with other researchers.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2019 (actual). Primary completion is estimated for Dec 2026, 91 months after the start.

Of 542 non-industry observational studies under Prostatic Neoplasms, half reached primary completion within 67 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 162. This study's planned 91 months is above that.

Counting every sponsor, half of 651 studies reached it within 60 months; a quarter within 28 and three quarters within 141.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 16, 2020
First posted
Apr 21, 2020
StartActual
May 29, 2019
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Feb 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04354064
Collaborators
Roche Sequencing Solutions, The Foundation for Barnes-Jewish Hospital, National Center for Advancing Translational Sciences (NCATS), Radiological Society of North America, Skandalaris, The V Foundation for Cancer Research, National Institute of General Medical Sciences (NIGMS)
Responsible party
Sponsor
First posted
Apr 21, 2020
Start date
May 29, 2019
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Feb 20, 2026

Study contacts

Melissa Reimers, M.D.
Contact
cbumb@wustl.edu
314-362-7249
Melissa Reimers, M.D.
principal investigator · Washington University School of Medicine

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion